Literature DB >> 2225367

Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study.

E L Alderman1, M G Bourassa, L S Cohen, K B Davis, G G Kaiser, T Killip, M B Mock, M Pettinger, T L Robertson.   

Abstract

The Coronary Artery Surgery Study (CASS) randomized 780 patients to an initial strategy of coronary surgery or medical therapy. Of medically randomized patients, 6% had surgery within 6 months and a total of 40% had surgery by 10 years. At 10 years, there was no difference in cumulative survival (medical, 79% vs. surgical, 82%; NS) and no difference in percentage free of death and nonfatal myocardial infarction (medical, 69% vs. surgical, 66%; NS). Patients with an ejection fraction of less than 0.50 exhibited a better survival with initial surgery treatment (medical, 61% vs. surgical, 79%; p = 0.01). Conversely, patients with an ejection fraction greater than or equal to 0.50 exhibited a higher proportion free of death and myocardial infarction with initial medical therapy (medical, 75% vs. surgical, 68%; p = 0.04) although long-term survival remained unaffected (medical, 84% vs. surgical, 83%; p = 0.75). There were no significant differences either in survival and freedom from nonfatal myocardial infarction, whether stratified on presence of heart failure, age, hypertension, or number of vessels diseased. Thus, 10-year follow-up results confirm earlier reports from CASS that patients with left ventricular dysfunction exhibit long-term benefit from an initial strategy of surgical treatment. Patients with mild stable angina and normal left ventricular function randomized to initial medical treatment (with an option for later surgery if symptoms progress) have survival equivalent to those patients randomized to initial surgery.

Entities:  

Mesh:

Year:  1990        PMID: 2225367     DOI: 10.1161/01.cir.82.5.1629

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  58 in total

1.  Long term prognosis of heart failure after acute coronary syndromes without ST elevation.

Authors:  M C Shibata; J Collinson; A K Taneja; A Bakhai; M D Flather
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

2.  Identification of advanced coronary artery disease with exercise myocardial perfusion imaging: the clinical value of a novel approach for assessing lung thallium-201 uptake.

Authors:  Efstratios Moralidis; Tryfon Spyridonidis; Georgios Arsos; Constantinos Anagnostopoulos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-23       Impact factor: 9.236

Review 3.  Will drug-eluting stents replace coronary artery bypass surgery?

Authors:  Ross M Reul
Journal:  Tex Heart Inst J       Date:  2005

4.  Coronary bypasses 10 years on.

Authors:  M C Petch
Journal:  BMJ       Date:  1991-09-21

Review 5.  The comparative efficacy of percutaneous and surgical coronary revascularization in 2009: a review.

Authors:  Stephen A May; James M Wilson
Journal:  Tex Heart Inst J       Date:  2009

6.  Outcome of medical versus invasive treatment strategies for non-high-risk ischemic heart disease.

Authors:  J H O'Keefe; T M Bateman; R W Ligon; J Case; J Cullom; C Barnhart; J Spertus
Journal:  J Nucl Cardiol       Date:  1998 Jan-Feb       Impact factor: 5.952

7.  Prognostic characterization of patients with mild coronary artery disease with myocardial perfusion single photon emission computed tomography: validation of an outcomes-based strategy.

Authors:  R Hachamovitch
Journal:  J Nucl Cardiol       Date:  1998 Jan-Feb       Impact factor: 5.952

Review 8.  Prognostic assessment in coronary artery disease: role of radionuclide angiography.

Authors:  R O Bonow
Journal:  J Nucl Cardiol       Date:  1994 May-Jun       Impact factor: 5.952

Review 9.  Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.

Authors:  J M Wilson; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1995

Review 10.  Advances in the surgical treatment of heart failure.

Authors:  Larry A Allen; G Michael Felker
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.